Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard
- 1 October 1994
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 32 (10) , 2494-500
- https://doi.org/10.1128/jcm.32.10.2494-2500.1994
Abstract
A comparative study of broth macro- and microdilution methods for susceptibility testing of fluconazole, itraconazole, flucytosine, and amphotericin B was conducted with 273 yeasts. The clinical isolates included 100 Candida albicans, 28 Candida tropicalis, 25 Candida parapsilosis, 15 Candida lusitaniae, 15 Candida krusei, 50 Cryptococcus neoformans var. neoformans, 25 Torulopsis (Candida) glabrata, and 15 Trichosporon beigelii strains. Both methods were performed according to the National Committee for Clinical Laboratory Standards' (NCCLS) recommendations (document M27-P). For fluconazole, itraconazole, and flucytosine, the endpoint was the tube that showed 80% growth inhibition compared with the growth control for the macrodilution method and the well with slightly hazy turbidity (score 1) compared with the growth control for the microdilution method. For amphotericin B, the endpoint was the tube and/or well in which there was absence of growth. For the reference macrodilution method, the MICs were determined after 48 h of incubation for Candida spp., T. glabrata, and T. beigelii and after 72 h for C. neoformans var. neoformans. For the microdilution method, either the first-day MICs (24 h for all isolates other than C. neoformans and 48 h for C. neoformans var. neoformans) or the second-day MICs (48 and 72 h, respectively) were evaluated. The agreement within one doubling dilution of the macrodilution reference for all drugs was higher with the second-day MICs than with the first-day MICs for the microdilution test for most of the tested strains. General agreement was 92% for fluconazole, 85.7% for itraconazole, 98.3% for flucytosine, and 96.4% for amphotericin B. For C. neoformans var. neoformans and T. beigelii, the agreement of the first-day reading was higher than that of the second-day reading for fluconazole (94 versus 92%, respectively, for C. neoformans var. neoformans, and 86.7 versus 80%, respectively, for T. beigelii). Our studies indicate that the microdilution technique performed following the NCCLS guidelines with a second-day reading is a valid alternative method for testing fluconazole, itraconazole, flucytosine, and amphotericin B against these eight species of yeasts.Keywords
This publication has 23 references indexed in Scilit:
- Resistance of Candida albicans to Fluconazole During Treatment of Oropharyngeal Candidiasis in a Patient with AIDS: Documentation by In Vitro Susceptibility Testing and DNA Subtype AnalysisClinical Infectious Diseases, 1994
- Improved medium for fluconazole susceptibility testing of Candida albicansAntimicrobial Agents and Chemotherapy, 1994
- Correlation between in vitro susceptibility ofCandida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993
- Fluconazole-Resistant Candida albicansClinical Infectious Diseases, 1993
- Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with FluconazoleNew England Journal of Medicine, 1991
- Emergence ofCandida krusei infections after therapy of oropharyngeal candidiasis with fluconazoleEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Candida albicans resistance in AIDSJournal of Infection, 1991
- Fluconazole resistant candida in AIDSJournal of Infection, 1991
- Fungal Infections in Cancer PatientsAnnals of the New York Academy of Sciences, 1988
- FLUCONAZOLE RESISTANCE IN CANDIDA GLABRATAThe Lancet, 1988